Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Feb 6, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce cardiac failure and hospital admission risk in patients with type 2 diabetes mellitus (T2DM). This benefit has not been demonstrated with other classes of T2DM treatments. SGLT2 inhibitors have been shown to reduce hospital admission due to cardiac failure by 30% compared to placebo. The most significant benefit was seen in patients with reduced left ventricular ejection fraction (EF). Also, SGLT2 inhibitors have been reported to reduce renal impairment progression by 45% compared to placebo. The mechanism of action of these effects has not yet been determined. Another study that looked at dapagliflozin cardiac risk reduction showed that mortality and hospitalization risks were reduced in patients without diabetes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.